CStone Pharmaceuticals: CSTONE ANNOUNCED NEW DRUG APPROVAL OF CEJEMLY (SUGEMALIMAB) IN CHINA TO POTENTIALLY RESHAPE THE LANDSCAPE OF IMMUNO-ONCOLOGY THERAPY IN LUNG CANCER

SUZHOU, China, Dec. 21, 2021 /PRNewswire/ -- CStone Pharmaceuticals (the "Company" or "CStone") is pleased to announce that the National Medical Products Administration ("NMPA") of China has

Related Keywords

China ,Taiwan ,Shanghai ,Suzhou ,Jiangsu ,Chinese ,Jason Yang ,Caicun Zhou ,Frank Jiang ,Pfizer ,U Ligand Corporation ,Prnewswire Cstone Pharmaceuticals The Company ,Drug Administration ,National Medical Products Administration ,Shareholders Of The Company ,Department Of Oncology ,Oncology Trends ,Principal Investigator ,Shanghai Pulmonary Hospital ,Chief Medical Officer ,Ligand Corporation ,Greater China ,Proffered Paper Oral Presentation ,Late Breaking Abstract ,Mini Oral Presentation ,Mainland China ,Breakthroughs That Change Patient ,Listing Rules ,Cstone ,Pharmaceuticals ,Stone ,Nnounced ,Drug ,Approval ,Cejemly ,Sugemalimab ,Potentially ,Preshape ,Landscape ,Immuno ,Ncology ,Therapy ,Young ,Dancer ,